The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, offering targeted exposure to U.S. companies that manufacture and distribute medical devices, including imaging equipment, prosthetics, and surgical tools. It holds about 52 stocks, with the top 10 making up over 75% of assets. Key positions include ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), and SYK (Stryker, ~11%). The portfolio is entirely allocated to healthcare, zeroing in on the medical devices subsector. This focus makes IHI particularly sensitive to industry challenges like reduced hospital spending and procedural delays, which has amplified its recent declines relative to more diversified healthcare ETFs.
In the last 30 days, IHI fell from around $54.35 to $49.77, marking a -8.5% decline. The path was volatile and downward-trending, with sharp drops in late April speeding up the selloff. Over the past quarter, the retreat was even steeper at -15% from near $58.50 levels, driven by steady erosion amid broader market shifts. These moves line up with trailing returns of -4.3% for the prior month and -14.9% for three months as of early May, pointing to a bearish, range-bound pattern with lower highs. From what I see, this confirms ongoing pressure in the space.
The ETF's downturn over the past 30 days came mainly from weakness in its largest holdings and sector headwinds. Top holding ISRG dropped over 2%, pulling IHI lower given its 16.5% weight, while EW (Edwards Lifesciences) slid on concerns about cardiac device demand. Gains in ABT (up significantly) and SYK offered some cushion, but the portfolio's concentration magnified the losses. Softer demand for implants and neurotechnology—evident in Stryker's Q1 earnings miss—added to the strain. On the macro side, high interest rates raised financing costs for growth-reliant medtech companies, spurring profit-taking. Net fund outflows and a shift in sentiment toward value sectors only intensified the pressure. I also checked this using Tickeron’s AI Screener to gauge how IHI stacks up against peers.
The -15% quarterly slide built from mounting pressures on medical devices, including stretched valuations after 2025 gains and tighter macro conditions. Holdings like ISRG and EW lagged due to slower procedural growth and supply chain hurdles, while higher rates discounted future cash flows for innovation-focused firms. Earnings from peers like Stryker showed weaker demand in orthopedics and surgery, diverging from broader healthcare strength. Institutional outflows reached hundreds of millions over the year, with assets under management shrinking from $3.5B+ peaks, signaling fading confidence. Longer-term issues like hospital budget limits and rotation to cyclicals deepened the underperformance against health benchmarks. One thing that stands out is how these dynamics have persisted.
In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs through filters on technical patterns, fundamentals, trends, volatility, and AI signals. It scans thousands of assets using criteria like industry, market cap, indicators, price patterns, and performance metrics, surfacing trade ideas, breakouts, and opportunities faster than manual methods. This has been invaluable for tracking sector performance and dynamic ETF moves like those in medical devices. I’m watching it closely for the next insights.
Looking forward, keep an eye on demand signals in medical devices, such as hospital procedure volumes and Q2 earnings from leaders like SYK and ISRG. The macro backdrop—Federal Reserve rate decisions and inflation—will shape valuations for growth names. Major holdings' progress in areas like robotic surgery adoption matters too. Supply chain stability and regulatory shifts could also influence the ETF. Risks persist from extended weak demand or outflows, but improved flows or rate cuts might aid a rebound. This is important because it frames the potential path.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
IHI moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on IHI as a result. In 70 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for IHI just turned positive on October 08, 2026. Looking at past instances where IHI's MACD turned positive, the stock continued to rise in 44 of 53 cases over the following month. The odds of a continued upward trend are 83%.
Following a +0.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHI advanced for three days, in 232 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The 10-day RSI Indicator for IHI moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
IHI broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IHI entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Category Health